OTC Obesity - Netherlands

Date: June 22, 2010
Pages: 32
Price:
US$ 990.00
Publisher: Euromonitor International Ltd
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O86A9A26AE3EN
Leaflet:

Download PDF Leaflet

Orlistat was switched in the Netherlands during 2008, paving the way for the introduction of OTC obesity products. In April 2009, GlaxoSmithKline introduced Alli in the Dutch market, being the sole product available OTC obesity at the time of writing.

Euromonitor International's OTC Obesity Products in Netherlands report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.

Product coverage:

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
  • Get a detailed picture of the Consumer Health industry;
  • Pinpoint growth sectors and identify factors driving change;
  • Understand the competitive environment, the market’s major players and leading brands;
  • Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town and Santiago and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
Executive Summary
Good Performance Sustained With Trends Towards Prevention and Faster Relief
Sports Nutrition Rises Fastest From A Small Base
Multinationals Focus on Innovations Amid the Strength of Private Label
Drugstores and the Internet Remain the Most Dynamic Channels
Steady Prospects Driven by Product Extensions Addressing Lifestyle Changes
Key Trends and Developments
Recession Poses A Threat To Consumer Health Industry
Product Switches Important in Driving Growth
Consumers Increasingly Go for Prevention
More Relaxed Regulation on Distribution of OTC Products
Swine Flu Fears Lead To Consumers Adopting More Cautious Approach
Market Indicators
  Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009
  Table 2 Life Expectancy at Birth 2004-2009
Market Data
  Table 3 Sales of Consumer Health by Sector: Value 2004-2009
  Table 4 Sales of Consumer Health by Sector: % Value Growth 2004-2009
  Table 5 Consumer Health Company Shares by Value 2005-2009
  Table 6 Consumer Health Brand Shares by Value 2006-2009
  Table 7 Penetration of Private Label by Sector 2004-2009
  Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009
  Table 9 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009
  Table 10 Forecast Sales of Consumer Health by Sector: Value 2009-2014
  Table 11 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014
Appendix
OTC Registration and Classification
Distribution
Vitamins and Dietary Supplements Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
  Summary 1 Consumer Health Switches 2007-2009
Definitions
  Summary 2 Research Sources
Chefaro International BV
Strategic Direction
Key Facts
  Summary 3 Chefaro International BV: Key Facts
Company Background
Production
Competitive Positioning
  Summary 4 Chefaro International BV: Competitive Position 2009
Galvastore BV
Strategic Direction
Key Facts
  Summary 5 Galvastore BV: Key Facts
  Summary 6 Galvastore BV: Operational Indicators
Company Background
Production
Competitive Positioning
Imgroma BV
Strategic Direction
Key Facts
  Summary 7 Imgroma BV: Key Facts
  Summary 8 Imgroma BV: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 9 Imgroma BV: Competitive Position 2009
Pharma Nord BV
Strategic Direction
Key Facts
  Summary 10 Pharma Nord BV: Key Facts
  Summary 11 Pharma Nord BV: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 12 Pharma Nord BV: Competitive Position 2009
Springfield Nutraceuticals
Strategic Direction
Key Facts
  Summary 13 Springfield Nutraceuticals BV: Key Facts
Company Background
Competitive Positioning
  Summary 14 Springfield Nutraceuticals BV: Competitive Position 2009
Trends
Category Data
  Table 12 Sales of OTC Obesity: Value 2009
  Table 13 OTC Obesity Company Shares by Value 2005-2009
  Table 14 OTC Obesity Brand Shares by Value 2006-2009
  Table 15 Forecast Sales of OTC Obesity: Value 2009-2014
  Table 16 Forecast Sales of OTC Obesity: % Value Growth 2009-2014
Skip to top


OTC Obesity - Australia US$ 990.00 Jun, 2010 · 33 pages
OTC Obesity - Austria US$ 990.00 Apr, 2010 · 31 pages
OTC Obesity - Denmark US$ 990.00 Apr, 2010 · 29 pages
OTC Obesity - France US$ 990.00 Apr, 2010 · 49 pages
OTC Obesity - Greece US$ 990.00 Mar, 2010 · 33 pages

Ask Your Question

OTC Obesity - Netherlands
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: